Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Aug 3, 2021, after the close
10-Q filed Aug 3, 2021, 34 days after period end · 0001558370-21-009976
| Metric | Q2 2021 | Q2 2020 | Q2 2019 | Q2 2018 |
|---|---|---|---|---|
| Revenue | $26.27M | $16.02M | $10.41M | $1.79M |
| Net Income | -$13.82M | -$17.58M | -$20.61M | -$25.56M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.08 |
| -$0.10 |
| -$0.12 |
| -$0.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
